What is Latuda© used for?

Latuda© is indicated for Schizophrenia, Bipolar I disorder (acute agitation, maintenance treatment, and depression).

Latuda© is developed by University of North Carolina, Chapel Hill.

What development phase is Latuda© in?

Latuda© is FDA-approved (marketed).

What are the side effects of Latuda©?

Common side effects include Akathisia, Somnolence, Parkinsonism, Nausea, Restlessness, Tremor.

Last reviewed 2026-04-22 · How we verify

Latuda©

University of North Carolina, Chapel Hill · FDA-approved active Small molecule

Latuda is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors while acting as a partial agonist at 5-HT1A receptors.

Latuda is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors while acting as a partial agonist at 5-HT1A receptors. Used for Schizophrenia, Bipolar I disorder depression, Bipolar I disorder maintenance treatment.

At a glance

Generic name	Latuda©
Also known as	Lurasidone Hydrochloride tablets
Sponsor	University of North Carolina, Chapel Hill
Drug class	Atypical antipsychotic
Target	Dopamine D2 receptor, serotonin 5-HT7 receptor, serotonin 5-HT1A receptor
Modality	Small molecule
Therapeutic area	Psychiatry
Phase	FDA-approved

Mechanism of action

By antagonizing dopamine D2 receptors, Latuda reduces psychotic symptoms associated with schizophrenia and bipolar disorder. Its additional serotonergic activity (5-HT7 antagonism and 5-HT1A partial agonism) may contribute to mood stabilization and reduced side effects compared to dopamine-selective antipsychotics. This multi-target profile is characteristic of second-generation antipsychotics.

Approved indications

Schizophrenia
Bipolar I disorder (acute agitation, maintenance treatment, and depression)

Common side effects

Akathisia
Somnolence
Parkinsonism
Nausea
Restlessness
Tremor

Key clinical trials

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

University of North Carolina, Chapel Hill portfolio CI